Over half a decade, Abbott Laboratories managed to grow its earnings per share at 12% a year. The EPS growth is more ...

To Dioselina Salto, the first two weeks of motherhood were amazing, even though she spent much of it in the hospital after ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of ...

On Friday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $116.59 which represents a slight increase of $1.29 or 1.12% from the prior close of $115.3. The stock opened at $115.

周一，巴克莱维持对Abbott Labs (NYSE:ABT)股票的增持评级，并将目标价从143美元上调至149美元。此次调整是在Abbott最近在圣路易斯的NEC诉讼中获得有利裁决后做出的。巴克莱分析师表示，尽管该股近期已有所上涨，包括从7月低点上涨18%，但距离他们对公司股票的新目标价仍有超过25%的上涨空间。

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Abbott Laboratories (NYSE:ABT), together with its subsidiaries, discovers, develops, manufactures and sells health care products worldwide. It is set to report its Q4 2024 earnings on Jan.